title: Prescription pattern of oxybutynin ER in patients with overactive bladder in real life practice: a multicentre, open-label, prospective observational study.
abstract: OBJECTIVE
  To investigate the prescription pattern and dose distribution of the antimuscarinic agent oxybutynin extended release (ER) in patients with overactive bladder (OAB) in actual clinical practice.
  
  
  METHODS
  In this multicentre, prospective, observational, flexible-dosing study, the dosage of oxybutynin ER for each patient was adjusted after discussions of efficacy and tolerability between doctor and patient, over a 12 week treatment period. Efficacy was measured by administering the Primary OAB Symptom Questionnaire (POSQ) before and after treatment. Patients were also administered, the patient perception of treatment benefit (PPTB) questionnaire at the end of the study. Adverse events (AE) were documented at each study visit.
  
  
  RESULTS
  Of the 809 patients enrolled, 590 (73.2%) continued to take study medication for 12 weeks. Most patients were prescribed 5 (24.2%) or 10 (68.8%) mg/day oxybutynin ER at the start of treatment. Most were also prescribed 5 (19.1%) or 10 (67.4%) mg/day at the end of treatment, with a dose escalation rate of 14.9%. All OAB symptoms evaluated by the POSQ were improved; 94.1% of patients reported benefits from treatment and 89.3% were satisfied. Independent predictive factors for discontinuation were female, younger age (age ≤ 65), obesity (BMI ≥ 25), severe symptoms (USS, Gr. 5) and larger numbers of other co-medications.
  
  
  CONCLUSIONS
  Most patients were prescribed 5-10 mg/day oxybutynin ER as both starting and maintenance doses, with a dose escalation rate of only 14.9%. Prescription of > 10 mg/day oxybutynin ER was not frequent in real life practice.
authors.affiliation: Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
authors.forename: D-S
authors.initials: DS
authors.lastname: Yoo
authors.forename: J-Y
authors.initials: JY
authors.lastname: Han
authors.forename: K-S
authors.initials: KS
authors.lastname: Lee
authors.forename: M-S
authors.initials: MS
authors.lastname: Choo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011446:Prospective Studies; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D003692:Delayed-Action Preparations; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin